A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma

Sponsor

H. Lee Moffitt Cancer Center and Research Institute (Other)

Overall Status

Terminated

CT.gov ID

NCT00361088

Collaborator

Millennium Pharmaceuticals, Inc. (Industry), National Cancer Institute (NCI) (NIH)

Enrollment

Location

Arms

Duration (Months)

1.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In Phase I, patients will receive a combination of PS-341 (Velcade) and R115777 (Zarnestra) to determine the dose limiting toxicity (DLT). Once DLT is determined, patients in Phase II will be receive the maximum tolerated dose (MTD) to complete 8 cycles of therapy. Treatment will continue if there is evidence of continued response for 8 cycles. Patients will receive follow up to include normal laboratory evaluations at least every 3 months and a skeletal survey will be performed at least every 6 months.

Condition or Disease	Intervention/Treatment	Phase
Multiple Myeloma	Drug: PS-341 Drug: R11577	Phase 1/Phase 2

Detailed Description

In Phase I, patients will receive intravenous PS-341 (Velcade) and 3 different dose levels of oral R115777 (Zarnestra). Dose Limiting Toxicity (DLT) will be determined over a period of one cycle and dose escalation to the next level will not occur until all patients projected at each level complete one cycle of therapy. Once DLT is determined, patients in Phase I and all patients enrolled for the phase II component will be treated at the maximum tolerated dose (MTD) to complete 8 cycles of therapy. Treatment will continue beyond 8 cycles if there is evidence of continued response. The study regimen will consist of two weeks of treatment followed by one week off for a total cycle duration of three weeks. If disease stabilization occurs (noted on 2 consecutive cycles) after the standard 8 cycles are given, treatment will be discontinued.

Patients are to be monitored for adverse events throughout the treatment phases and for a minimum of 30 days after their last dose of drugs. Follow up will include history and physical exam with laboratory evaluation at least every 3 months. Laboratories will include CMP, CBC, SPEP, UPEP, and quantitative immunoglobulins. A skeletal survey will be performed at least every 6 months.

Study Design

Study Type:

Interventional

Actual Enrollment :

42 participants

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Dose Escalation of Zarnestra (R115777) Combined With Velcade® (PS-341) in Patients With Relapsed Multiple Myeloma

Study Start Date :

Aug 1, 2005

Actual Primary Completion Date :

Jun 1, 2007

Actual Study Completion Date :

Jun 1, 2007

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Phase I	Drug: PS-341 Phase I and II: 1.3mg/m2 iv days 1,4,8,11 Other Names: bortezomib Velcade® Drug: R11577 Phase I: 100mg po BID days 1014 for Cohort 1, 200mg po BID days 1014 for Cohort 2, 300mg po BID days 1014 for Cohort 3. Phase II: Maximum Tolerated Dose (MTD) Other Names: Zarnestra
Experimental: Phase II	Drug: PS-341 Phase I and II: 1.3mg/m2 iv days 1,4,8,11 Other Names: bortezomib Velcade® Drug: R11577 Phase I: 100mg po BID days 1014 for Cohort 1, 200mg po BID days 1014 for Cohort 2, 300mg po BID days 1014 for Cohort 3. Phase II: Maximum Tolerated Dose (MTD) Other Names: Zarnestra

Arm

Intervention/Treatment

Experimental: Phase I

Drug: PS-341

Phase I and II: 1.3mg/m2 iv days 1,4,8,11

Other Names:

bortezomib

Velcade®

Drug: R11577

Phase I: 100mg po BID days 1014 for Cohort 1, 200mg po BID days 1014 for Cohort 2, 300mg po BID days 1014 for Cohort 3. Phase II: Maximum Tolerated Dose (MTD)

Other Names:

Zarnestra

Experimental: Phase II

Drug: PS-341

Phase I and II: 1.3mg/m2 iv days 1,4,8,11

Other Names:

bortezomib

Velcade®

Drug: R11577

Phase I: 100mg po BID days 1014 for Cohort 1, 200mg po BID days 1014 for Cohort 2, 300mg po BID days 1014 for Cohort 3. Phase II: Maximum Tolerated Dose (MTD)

Other Names:

Zarnestra

Outcome Measures

Primary Outcome Measures

Dose Limiting Toxicity (DLT) [Average of 6 months]
Determine the dose limiting toxicity at 3 weeks post treatment
Maximum Tolerated Dose [Average of 6 months]
Determine the maximum tolerated dose
Response Rates [Average of 6 months]
Determine response rates after 8 cycles of treatment
Toxicity [Average of 6 months]
Determine toxicity profiles

Secondary Outcome Measures

Progression Free Survival [Average of 12 months]
Determine progression free survival

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Voluntary written informed consent
Female subject is either post-menopausal/surgically sterilized or willing to use an acceptable method of birth control for the duration of the study.
Male subject agrees to use an acceptable method for contraception for the duration of the study.
Diagnosis of stage II or III multiple myeloma and have relapsed after at least one prior therapies confirmed by the presence of:

A new lytic lesion
A 25% increase in urine or serum monoclonal protein

Patient can have received PS-341 (Velcade) previously and does not require a previous response.
Patients must have measurable disease. One or more of the following must be present to qualify for this study:

Serum M-component greater than or equal to 1.0 gm/dl (10.0 g/L) by serum protein electrophoresis
Urine M-protein excretion > 200 mg/24 (0.2 g/24h) hours, by urine protein electrophoresis
Abnormal serum free light chain ratio with elevated Kappa or Lambda light chains in serum

Baseline measurements must be done within 21 days of study entry.
Karnofsky Performance Status Scale > 60.
Greater than or equal to 18 years of age.
Expected survival of greater than 8 weeks.
Swallow intact study medication tablets.
Can follow directions or has a caregiver who will be responsible for administering study medication.

Exclusion Criteria:

Previously treated with R115777 (Zarnestra).
Undergone an allogeneic bone marrow transplant.
A platelet count of <100,000 x 10 to the 9 power/L within 14 days before enrollment.
Absolute neutrophil count of <1.0 x 10 to the 9 power/L within 14 days before enrollment.
Measured creatinine > 1.5 X the upper limits of normal within 14 days before enrollment.
Greater than or equal to Grade 2 peripheral neuropathy within 14 days before enrollment.
Hypersensitivity to bortezomib, boron, mannitol or imidazole compounds
Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening.
Received other investigational drugs within 14 days of enrollment or immunotherapy within 30 days of enrollment.
Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
Ongoing radiation therapy or radiation therapy within 14 days prior to first treatment.
Cytotoxic chemotherapy within 30 days prior to first treatment.
Therapy with high-dose corticosteroids within 14 days prior to first treatment.
Presence of any of the following excludes a patient from entering the study until such condition is resolved (determined within 14 days prior to the first treatment):

Elevated total bilirubin > 2mg/dl, or direct bilirubin > 2 times the ULN.
Serum glutamic oxaloacetic transaminase (AST, formerly SGOT) or serum glutamic pyruvic transaminase (ALT, formerly SGPT) > 2 times the ULN
Serum calcium > 12 mg/dL.
Concurrent serious infection.
Life-threatening illness (unrelated to tumor).

History of any other ACTIVE and INVASIVE cancer other than the present condition (except non-melanoma skin cancer), unless in complete remission and off of all therapy for that disease for a minimum of 3 years.
Prohibited/allowable medications or precautions:

Enzyme-inducing anti-epileptic medications (e.g. phenytoin, phenobarbital, carbamazepine) are not allowed.
Non-enzyme anti-epileptic medications will be allowed.